CD274 and hereditary clear cell renal cell carcinoma: Despite there being a significantly fewer number of studies retrieved for other solid tumours, the PD-L1 testing approach was also cost-effective in some settings for urothelial cancer patients first-line treated with avelumab and pembrolizumab but also for renal cell carcinoma treated with nivolumab.